OTUD5

OTUD5 (DUBA) is a phosphorylation-activated OTU-family deubiquitinase that cleaves K48- and K63-linked polyubiquitin chains from a broad array of substrates to regulate innate immunity, DNA damage repair, chromatin remodeling, ferroptosis, and mTOR signaling. Phosphorylation at Ser177 (by mTOR and other kinases) cooperates with ubiquitin binding to fold the catalytic domain into its active conformation, and a ubiquitin-interaction motif (UIM) is required for efficient substrate processing (PMID:22245969, PMID:17991829, PMID:33110214). In innate immune signaling, OTUD5 removes K63-linked chains from TRAF3 to limit type I IFN production, stabilizes STING via K48-chain cleavage to sustain cGAS–STING signaling, removes K63-linked chains from TAK1 to suppress NF-κB activation, and stabilizes NOD2/RIPK2 to maintain NOD2-dependent responses (PMID:17991829, PMID:32879469, PMID:38937512, PMID:40240520). In DNA repair and chromatin biology, OTUD5 stabilizes Ku80 to promote NHEJ, scaffolds the FACT–HDAC1/2 complex at replication forks to limit R-loops and replication stress, represses transcription at double-strand breaks through UBR5 stabilization and FACT recruitment, and counteracts proteasomal degradation of chromatin regulators ARID1A/B, HDAC2, HCF1, and GSK3β during neural development—loss-of-function mutations cause LINKED syndrome, a developmental disorder (PMID:30980112, PMID:37713620, PMID:30508113, PMID:33523931, PMID:41851816).

1. 2007 High

   The first function assigned to OTUD5 was as a K63-linkage-selective deubiquitinase of TRAF3, establishing it as a negative regulator of type I interferon signaling—this defined OTUD5 as an immune-regulatory DUB and identified its UIM as essential for activity.

   Evidence siRNA screen, co-IP, in vitro DUB assay, and gain/loss-of-function in human cells

   PMID:17991829

   Open questions at the time

   • Kinase responsible for activating OTUD5 was unknown
   • Whether OTUD5 also processes K48 chains was untested
   • In vivo immune phenotype not yet examined
2. 2012 High

   Structural resolution of how OTUD5 is activated revealed that Ser177 phosphorylation and ubiquitin C-terminal tail binding cooperatively fold the catalytic domain around its substrate—an unprecedented mechanism among proteases that explained the phospho-dependence observed in functional studies.

   Evidence Crystal structure of OTUD5–ubiquitin-aldehyde adduct, phosphorylation-site mutagenesis, in vitro DUB assay

   PMID:22245969

   Open questions at the time

   • Identity of the physiological kinase(s) for Ser177 remained open
   • Structural basis for linkage selectivity was not fully resolved
   • How phosphorylation is regulated in vivo was unknown
3. 2013 Medium

   Extending OTUD5 beyond innate immunity, identification of p53 and PDCD5 as substrates showed that OTUD5 stabilizes key apoptotic regulators during DNA damage, establishing a role in the genotoxic stress response.

   Evidence Co-IP, ubiquitination assays, knockdown epistasis in DNA-damage-treated cells

   PMID:24143256 PMID:25499082

   Open questions at the time

   • Whether OTUD5 regulation of p53 operates in vivo was not tested
   • Relative contribution versus other p53 DUBs was unclear
   • Chain-linkage specificity on p53 was not determined
4. 2014 High

   Discovery of a reciprocal OTUD5–UBR5 regulatory circuit in T cells revealed that OTUD5 stabilizes the E3 ligase UBR5, which in turn controls RORγt ubiquitination and IL-17A production, providing the first in vivo genetic evidence (T cell-specific knockout) for OTUD5 function in adaptive immunity.

   Evidence Co-IP, T cell-specific Duba-deficient mice, ubiquitination assay, cytokine measurement

   PMID:25470037

   Open questions at the time

   • Whether UBR5 stabilization is a general mechanism at other OTUD5 substrates was not known
   • Phosphorylation status of OTUD5 in T cell activation was not addressed
5. 2019 High

   Two studies established OTUD5 as a DNA damage response factor: it localizes to DSBs where it scaffolds FACT (SPT16) and stabilizes UBR5 to repress RNA Pol II transcription at damaged chromatin, and separately stabilizes Ku80 to promote NHEJ—revealing dual catalytic and scaffolding roles in genome maintenance.

   Evidence DUB RNAi screen, ChIP, RNA synthesis assay at DSBs, domain mapping; Co-IP and NHEJ/HR reporter assays

   PMID:30508113 PMID:30980112

   Open questions at the time

   • Whether OTUD5 scaffolding versus DUB activity are independently regulated was unclear
   • Relationship between Ku80 stabilization and transcription repression at DSBs was not integrated
   • Role in HR versus NHEJ choice in vivo was not defined
6. 2020 High

   Conditional knockout studies demonstrated that OTUD5 stabilizes STING via K48-chain removal, sustaining type I IFN signaling in vivo, while a parallel study identified an mTOR–OTUD5 positive feedback loop (mTOR phosphorylates and activates OTUD5; OTUD5 stabilizes βTrCP1 to degrade DEPTOR), connecting OTUD5 to growth and metabolic signaling.

   Evidence Myeloid-specific Otud5 KO mice with viral infection/tumor challenge; Co-IP, ubiquitination assays, Drosophila genetic epistasis for mTOR pathway

   PMID:32879469 PMID:33110214

   Open questions at the time

   • Whether mTOR is the sole activating kinase for Ser177 in all contexts was unresolved
   • Cross-talk between immune and mTOR functions of OTUD5 was not explored
   • TRIM25–PML axis link (PMID:32826889) requires independent confirmation
7. 2021 High

   OTUD5 was shown to protect chromatin regulators (ARID1A/B, HDAC2, HCF1) from K48-linked proteasomal degradation during neuroectodermal differentiation, and loss-of-function mutations were identified as the cause of LINKED syndrome—a human developmental disorder—establishing OTUD5 as essential for chromatin accessibility at lineage-specific enhancers.

   Evidence Patient genomic sequencing, iPSC differentiation, ATAC-seq, ubiquitination assays with patient variant validation

   PMID:33523931

   Open questions at the time

   • Full spectrum of OTUD5 substrates relevant to neurodevelopment was not catalogued
   • Whether SWI/SNF complex integrity is the primary downstream effector was not determined
   • Rescue of patient cells by wild-type OTUD5 re-expression was not shown
8. 2023 High

   Multiple studies revealed OTUD5 as a ferroptosis gatekeeper: it stabilizes GPX4 (the master anti-ferroptotic enzyme) and SLC7A11 (cystine transporter) via K48-chain removal, and its own degradation during ischemia-reperfusion triggers ferroptotic cell death—providing a unified mechanism linking OTUD5 loss to oxidative cell death in kidney injury and cancer.

   Evidence Spatial transcriptomics, Co-IP, KO and AAV rescue in mouse I/R model; linkage-specific ubiquitination assays for SLC7A11

   PMID:37537342 PMID:38110369

   Open questions at the time

   • Whether GPX4 and SLC7A11 stabilization are coordinated or context-dependent was unclear
   • OTUD5 regulation of ferroptosis in non-renal tissues was not systematically studied
9. 2023 High

   iPOND-based replication fork proteomics revealed that OTUD5 assembles a FACT–HDAC1/2 complex at replication forks via its disordered C-terminal tail, limiting H4K16 acetylation, FACT loading, and R-loop formation—uncoupling this interaction activates the Fanconi Anemia pathway, linking OTUD5 to replication stress suppression.

   Evidence DUB depletion screen, iPOND, Co-IP, R-loop detection, H4K16ac ChIP, engineered disruption of OTUD5-FACT interaction

   PMID:37713620

   Open questions at the time

   • Whether OTUD5 DUB activity is required at forks or only scaffolding was not fully separated
   • Relationship between replication fork role and DSB transcription repression role was not integrated
10. 2024 High

    Site-specific biochemistry demonstrated that OTUD5 cleaves K63-linked ubiquitin from TAK1 at K158 via its catalytic C224 residue, preventing TAK1 phosphorylation and NF-κB activation; a scaffolding role promoting α-synuclein clearance via NEDD4-mediated K63-ubiquitination and endolysosomal degradation (independent of DUB activity) was also identified, broadening OTUD5 function to neurodegeneration.

    Evidence Mass spectrometry, active-site mutagenesis, podocyte-specific KO for TAK1; catalytic-dead mutant analysis and conditional KO in dopaminergic neurons for α-synuclein

    PMID:38937512 PMID:39721018

    Open questions at the time

    • Whether the non-catalytic scaffolding role for α-synuclein generalizes to other substrates is unknown
    • Full in vivo neuroprotective efficacy of OTUD5 modulation remains to be quantified
11. 2025 Medium

    Recent work extended OTUD5 into additional inflammatory and metabolic contexts: it stabilizes IRAK1 in microglia to drive NF-κB/MAPK neuroinflammation, sustains NOD2/RIPK2 innate sensing in macrophages, and stabilizes GSK3β in neural progenitor cells—with a patient-derived V233M OTU-domain variant confirming catalytic impairment as pathogenic.

    Evidence Microglial-specific KO with stroke/LPS models; macrophage-specific KO with MDP stimulation; patient iPSC-derived NPCs with isogenic CRISPR controls

    PMID:40240520 PMID:40755418 PMID:41851816

    Open questions at the time

    • Systematic identification of all OTUD5-dependent substrates across tissues has not been performed
    • How OTUD5 achieves substrate selectivity among dozens of reported targets is mechanistically unresolved
    • Therapeutic modulation of OTUD5 activity has not been demonstrated with small molecules

• Key unresolved questions include how OTUD5 achieves substrate selectivity given its remarkably broad substrate repertoire, whether its catalytic and scaffolding functions are independently regulated in different cellular contexts, and whether pharmacological modulation of its phosphorylation-dependent activation is feasible.
• No structural basis for substrate discrimination among diverse targets
• No small-molecule modulator of OTUD5 activity reported
• Tissue-specific versus universal functions not systematically delineated